VERAVEC Trademark

Trademark Overview

On Friday, May 8, 2015, a trademark application was filed for VERAVEC with the United States Patent and Trademark Office. The USPTO has given the VERAVEC trademark a serial number of 86623377. The federal status of this trademark filing is SECTION 8 - ACCEPTED as of Friday, February 25, 2022. This trademark is owned by Angiocrine Bioscience. The VERAVEC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Biological research; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research services
veravec

General Information

Serial Number86623377
Word MarkVERAVEC
Filing DateFriday, May 8, 2015
Status701 - SECTION 8 - ACCEPTED
Status DateFriday, February 25, 2022
Registration Number5014003
Registration DateTuesday, August 2, 2016
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 22, 2015

Trademark Statements

Translation of Words in MarkThe wording 'VERAVEC" has no meaning in a foreign language.
Goods and ServicesBiological research; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, May 16, 2015
Primary Code042
First Use Anywhere DateMonday, April 1, 2013
First Use In Commerce DateMonday, April 1, 2013

Trademark Owner History

Party NameAngiocrine Bioscience
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameAngiocrine Bioscience
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92172
Party NameAngiocrine Bioscience
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10065

Trademark Events

Event DateEvent Description
Tuesday, May 12, 2015NEW APPLICATION ENTERED
Saturday, May 16, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 11, 2015ASSIGNED TO EXAMINER
Wednesday, September 2, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 17, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 12, 2016USE AMENDMENT FILED
Tuesday, August 11, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 22, 2015PUBLISHED FOR OPPOSITION
Tuesday, September 22, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, May 11, 2016TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, May 11, 2016APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, May 12, 2016TEAS STATEMENT OF USE RECEIVED
Monday, June 6, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 13, 2016STATEMENT OF USE PROCESSING COMPLETE
Friday, February 25, 2022REGISTERED - SEC. 8 (6-YR) ACCEPTED
Friday, February 25, 2022NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Thursday, June 30, 2016ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, July 1, 2016NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, August 2, 2016REGISTERED-PRINCIPAL REGISTER
Monday, August 2, 2021COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, September 1, 2021TEAS SECTION 8 RECEIVED
Friday, February 25, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, November 7, 2022SEC. 15 ACKNOWLEDGEMENT - E-MAILED
Saturday, August 2, 2025COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Monday, November 7, 2022REGISTERED - SEC. 15 ACKNOWLEDGED
Friday, July 29, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 29, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 29, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, October 3, 2022TEAS SECTION 15 RECEIVED
Wednesday, November 2, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL

Related Keywords

veravec research pharmaceutical services fields biotechnology biological development